AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05644496
Drug: Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release
RxNorm normalized name: bupivacaine-meloxicam 400 mg-12 mg/14 mL injectable solution, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of the drug into the knee joint capsule and surrounding tissues after placing the knee prosthesis and before close of the surgical wound
Trial: NCT04976036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oral placebo soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
Trial: NCT04913831
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physiological saline 100ml, 8-35 days, once/day, intravenous administration
Trial: NCT06508749
Drug: VRC07-523LS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Antibody Infusion based on subject's weight
Trial: NCT00729768
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating doses
Trial: NCT04654065
Drug: IN-C004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time dose of IN-C004 taken orally.
Trial: NCT06494072
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.
Trial: NCT05008224
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles in all participants after PET scan 2 and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).~35 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive, \<60 years of age).
Trial: NCT05008224
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Trial: NCT00124098
Drug: Aranesp® (darbepoetin alfa)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05464784
Drug: MN-001
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MN-001 is a novel, orally bioavailable small molecule compound
Trial: NCT05464784
Drug: MN-001 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo tablet is identical in appearance to the MN-001 tablet, and contains excipients of MN-001.
Trial: NCT06379893
Drug: Voltaren Gel 1% (diclofenac sodium) (US only)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the US will use Volatren Gel containing 1% diclofenac sodium.
Trial: NCT06379893
Drug: Voltaren Gel 1.16% (diclofenac diethylammonium) (EU only)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the EU will use Volatren Gel containing 1.16% diclofenac diethylammonium.
Trial: NCT06379893
Drug: Voltaren Gel 2.32% (diclofenac diethylammonium) (EU only)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the EU will use Volatren Gel containing 2.32% diclofenac diethylammonium.
Trial: NCT05736367
Drug: U-13C-glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discover new insights into the glucose, TCA cycle, amino acid, and lipid metabolic dependencies of HR+/Her2- breast cancer, via liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy analysis of in vivo U-13C-glucose-labeled biopsy of tumor and benign adjacent tissue
Trial: NCT05324982
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be orally self-administered by study participants.
Trial: NCT05378503
Drug: Qsymia 3.75Mg-23Mg Extended Release Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From W0 to W2, once a daily.
Trial: NCT05378503
Drug: Qsymia 7.5Mg-46Mg Extended Release Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. From W2 to W14, once a daily.~2. At W14, if the weight loss rate is 3% or more, from W14 to W56(the end of visit), once a daily.
Trial: NCT05378503
Drug: Qsymia 11.25Mg-69Mg Extended Release Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At W14, if the weight loss rate is NOT 3% or more, from W14 to W16, once a daily.
Trial: NCT05378503
Drug: Qsymia 15Mg-92Mg Extended Release Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At W14, if the weight loss rate is NOT 3% or more, from W16 to W56(the end of visit), once a daily.
Trial: NCT05378503
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From W0(Randomisation) to W56(the End of visit) once a daily.
Trial: NCT06613659
Drug: traditional Chinese medicine (TCM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.
Trial: NCT06613659
Drug: non traditional Chinese medicine (non-TCM)
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.
Trial: NCT06696859
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacterial culture (sputum ,blood and pleural fluid) Antibiotics sensitivity tests
Trial: NCT06696586
Drug: Fentanyl infusion
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: will received lidocaine with dose 250 mg and fentanyl infusion in dose of 200 µg in rate 10ml /hr using 50ml syringe pump.
Trial: NCT06696586
Drug: Fentanyl Injection
RxNorm normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: will receive lidocaine 250 mg in addition to fentanyl injection in dose 100 µg by shots
Trial: NCT06319456
Drug: Cyclophosphamide，CTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 28 days for a treatment cycle, administration of 6 cycles.
Trial: NCT05300269
Drug: SHR-1701；Capecitabine；Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation: Radiation therapy 50.4Gy in 28 fractions to the pelvis on Days 1-5 every week. Drug: Capecitabine Capecitabine 825mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.~Drug:SHR-1701 Drug: Capecitabine (XELOX) Capecitabine 1000mg/m\^2 orally twice daily (bid) day1-day14, q3w. Drug: Oxaliplatin Oxaliplatin 130mg/m\^2, day1, iv, q3w
Trial: NCT00507364
Drug: Local injection of activated macrophages to anal fissure
RxNorm normalized name: eptacog alfa activated Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06031363
Drug: Indomethacin Suppository
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the regular dose group are given indomethacin suppository 100 mg anal plug immediately after operation, patients in the low dose group are given indomethacin suppository 50 mg anal plug immediately after operation, and patients in the high dose group are given indomethacin suppository 150 mg anal plug immediately after operation.
Trial: NCT05569720
Drug: ApTOLL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ApTOLL will be administered as follows:~* Day 1: a dose of 0.1mg/kg will be administered intravenously as a slow infusion.~* Day 2: a dose of 0.1mg/kg will be administered intravenously as single bolus injection.~* Day 3: a dose of 0.2mg/kg will be administered intravenously as single bolus injection.
Trial: NCT06099535
Drug: LNK01001 Dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules taken orally
Trial: NCT06099535
Drug: LNK01001 Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules taken orally
Trial: NCT06099535
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules taken orally
Trial: NCT06383520
Drug: 68Ga-aGPC3-scFv/Fab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For pharmacokinetics, healthy volunteer underwent PET imaging targeting GPC3. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~For Cancer patients, subjects should have targeting GPC3 and 18F-FDG PET scans two days apart.~Blood tests, liver and kidney function, tumor markers (AFP, etc.), and other biochemical markers must be performed one week prior to and after imaging.~Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis.
Trial: NCT05110664
Drug: Placibo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo solution
Trial: NCT04832425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT05259917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to KVD900 Tablet
Trial: NCT05259917
Drug: KVD900 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KVD900 Tablet 600 mg (2 x 300 mg)
Trial: NCT05259917
Drug: KVD900 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KVD900 Tablet 300 mg (1 x 300 mg)
Trial: NCT04947423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will self-administer DPI-386 Nasal Gel or Placebo
Trial: NCT05731310
Drug: Angong Niuhuang Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take Angong Niuhuang pill half a pill/day； Angong Niuhuang pill combined with music scalp acupuncture group These operations last for 4 weeks
Trial: NCT05283434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill placebo
Trial: NCT05126316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
Trial: NCT05725200
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Trial: NCT04737174
Drug: ES-481
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28-day screening period followed by 4-week dose escalation period followed by 16-week treatment period followed by 4-week dose washout period
Trial: NCT05725200
Drug: Petrozumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Trial: NCT04570085
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg caffeine capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks (by 100mg stages) until 400mg aim dose per day in 2 doses during 27 weeks, and finally interrupt according to the same negative titration.
Trial: NCT04570085
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks until 2 doses aim dose per day during 27 weeks, and finally interrupt according to the same negative titration.
Trial: NCT05650502
Drug: saisonal malaria chimoprevention
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigate the impact of saisonal malaria chimoprevention on children anti PfEMP1 construction and maintenance and their succeptibility to malaria infection
Trial: NCT05123716
Drug: placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given a placebo capsule that will only contain lactose.
Trial: NCT06176339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be administered orally three times per day through the time of the chemotherapy cycles.
Trial: NCT06203769
Drug: 14-day antibiotic therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The studied intervention will be 14-day antibiotic therapy after removal of infected material
Trial: NCT06203769
Drug: 28-day antibiotic therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The comparator arm will be 28-day antibiotic therapy after removal of infected material
Trial: NCT05765032
Drug: SHR-A1921；
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SHR-A1921 administered as an IV infusion Drug: Adebrelimab administered as an IV infusion Drug: Carboplatin administered as an IV infusion Drug: Cisplatin administered as an IV infusion Drug: Bevacizumab administered as an IV infusion
Trial: NCT06308978
Drug: FT819
RxNorm normalized name: Furmonertinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FT819 will be administered as a single-dose intravenous (IV) infusion at planned dose levels.
Trial: NCT06308978
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as an IV infusion at planned dose levels.
Trial: NCT05305911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for six months
Trial: NCT05183555
Drug: 68Ga-DOTATOC PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga-DOTATOC PET/CT will be recorded the following day of 18F-FDG PET/CT if patient signed the consent
Trial: NCT06475235
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anti-metabolite, 50 mL vials, via intravenous infusion per protocol.
Trial: NCT05211284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to Placebo arm will receive Placebo treatment until the duration of study (24 weeks).
Trial: NCT05923996
Drug: microbotox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be treated by single session of microbotox injection
Trial: NCT05374278
Drug: [18F]RP-115 PET/MRI or PET/CT and MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An I.V. bolus injection of up to 10 millicurie (mCi) \[18F\]RP-115 will be administered, followed by a PET/MRI scan or by a combination of PET/CT and MRI
Trial: NCT05709015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of mouthwash containing placebo twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
Trial: NCT05211830
Drug: SXR1096 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin cream to be applied twice a day to a predefined area of the skin
Trial: NCT05211830
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin cream to be applied twice a day to a predefined area of the skin
Trial: NCT05739916
Drug: DA-1229_01 5/1000mg (Before)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT05739916
Drug: DA-1229_01 5/1000mg (After)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT06042010
Drug: Oral zinc supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients received oral Zinc picolinate 50mg for 6 weeks as single morning dose along with 0.1%
Trial: NCT04634656
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery
Trial: NCT06081101
Drug: Ketorolac Injection
RxNorm normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication will be injected into SI joint under ultrasound guidance
Trial: NCT05902624
Drug: Hepatitis B Virus Vaccine(HBV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B Virus Vaccine(HBV)
Trial: NCT06614153
Drug: HRG2010(II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRG2010(II)
Trial: NCT06614153
Drug: Sustained-release Carbidopa/Levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release Carbidopa/Levodopa
Trial: NCT06685185
Drug: NNC0363-1063
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0363-1063 will be administered subcutaneously.
Trial: NCT06685185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously.
Trial: NCT06697535
Drug: Oral Glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally with a tapered dosing schedule, as specified in the Standard Dose Glucocorticoids arm, with adjustments based on participant response.
Trial: NCT04956809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
Trial: NCT00329316
Drug: Crinone Gel 8%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06696755
Drug: Icalcaprant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsules
Trial: NCT06696755
Drug: Placebo for Icalcaprant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsules
Trial: NCT04811651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous placebo solution with the same appearance as the treatment group.
Trial: NCT05670444
Drug: kelavit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment group received two pills in the morning containing Vit C Vit D zinc and minerals and one pill of 2 mg of melatonin in the evening
Trial: NCT05269329
Drug: XC8, film-coated tablets, 20 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day (1 tablet twice a day)
Trial: NCT05269329
Drug: XC8, film-coated tablets, 40 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day (2 tablets twice a day)
Trial: NCT05269329
Drug: XC8, film-coated tablets, 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day (4 tablets twice a day)
Trial: NCT05269329
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, 2, or 4 tablets twice a day
Trial: NCT05625594
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04058210
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet for oral administration.
Trial: NCT05229510
Drug: 50 mg/mL Virazole Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted
Trial: NCT05229510
Drug: 100 mg/mL Virazole Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted
Trial: NCT05229510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 or 20 ml total volume) aerosolized and administered until solution depleted
Trial: NCT06157450
Drug: ZSP1273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive ZSP1273 orally.
Trial: NCT04371653
Drug: PRIM-DJ2727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration orally
Trial: NCT04371653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration orally placebo
Trial: NCT05472948
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be given 2 weeks on/1 week off (1000 mg/m2 BID po.)
Trial: NCT06494527
Drug: RG002C0106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG002C0106 is a siRNA drug targeting complement C3 to silence the related gene through the RNA interfering mechanism and inhibit the expression of C3 protein.
Trial: NCT05882032
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.